Drug details
Margenza (margetuximab-cmkb injection, for intravenous use)
type of Antineoplastics, Anti-HER2
Margenza (margetuximab-cmkb) is a HER2/neureceptor antagonist indicated, in combination with chemotherapy, to treat adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
This drug may have the following side effects:
- nausea,
- vomiting,
- diarrhea,
- fever,
- shortness of breath,
- constipation,
- headache,
- fatigue,
- weakness,
- cough,
- abdominal pain,
- hair loss,
- infusion-related reactions,
- joint or muscle pain,
- decreased appetite,
- numbness and tingling in extremities,
- hand-foot syndrome (palmar-plantar erythrodysesthesia), and
- extremity pain
The following drugs are related to Margenza, either as a replacement or used together:
- Kadcyla (ado-trastuzumab emtansine injection for iv use)
- Afinitor (everolimus tablets)
- Afinitor Disperz (everolimus tablets)
- Aredia (pamidronate disodium)
- Aromasin (exemestane)
- Ellence (epirubicin hydrochloride)
- Enhertu (fam-trastuzumab deruxtecan-nxki for injection)
- Halaven Injection (eribulin mesylate)
- Fareston (toremifene)
- Faslodex (fulvestrant)
- Femara (letrozole)
- Infugem (gemcitabine in sodium chloride injection)
- Ixempra (ixabepilone)
- Keytruda (pembrolizumab for injection)
- Lynparza (olaparib capsules for oral administration)
- Nerlynx (neratinib tablets)
- Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection)
- Trodelvy (sacituzumab govitecan-hziy for injection, for iv use)
- Soltamox (tamoxifen citrate)